| Infliximab and methotrexate in the treatment of rheumatoid arthritis PE Lipsky, DMFM van der Heijde, EW St. Clair, DE Furst, FC Breedveld, ... New England Journal of Medicine 343 (22), 1594-1602, 2000 | 4061 | 2000 |
| Role of cytokines in rheumatoid arthritis M Feldmann, FM Brennan, RN Maini Annual review of immunology 14 (1), 397-440, 1996 | 3928* | 1996 |
| Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase … R Maini, EW St Clair, F Breedveld, D Furst, J Kalden, M Weisman, ... The Lancet 354 (9194), 1932-1939, 1999 | 3100 | 1999 |
| An inflammatory cytokine signature predicts COVID-19 severity and survival DM Del Valle, S Kim-Schulze, HH Huang, ND Beckmann, S Nirenberg, ... Nature medicine 26 (10), 1636-1643, 2020 | 2268 | 2020 |
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis MJ Elliott, RN Maini, M Feldmann, JR Kalden, C Antoni, JS Smolen, ... The Lancet 344 (8930), 1105-1110, 1994 | 2204 | 1994 |
| Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor α monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid arthritis RN Maini, FC Breedveld, JR Kalden, JS Smolen, D Davis, JD MacFarlane, ... Arthritis & Rheumatism: Official Journal of the American College of …, 1998 | 2173 | 1998 |
| Anti-TNFα therapy of rheumatoid arthritis: what have we learned? M Feldmann, RN Maini Annual review of immunology 19 (1), 163-196, 2001 | 1780 | 2001 |
| Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity GF Bottazzo, T Hanafusa, R Pujol-Borrell, M Feldmann The Lancet 322 (8359), 1115-1119, 1983 | 1557 | 1983 |
| Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α MJ Elliott, RN Maini, M Feldmann, A Long‐Fox, P Charles, P Katsikis, ... Arthritis & Rheumatism 36 (12), 1681-1690, 1993 | 1500 | 1993 |
| IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses T Krausgruber, K Blazek, T Smallie, S Alzabin, H Lockstone, N Sahgal, ... Nature immunology 12 (3), 231-238, 2011 | 1414 | 2011 |
| Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. RO Williams, M Feldmann, RN Maini Proceedings of the National Academy of Sciences 89 (20), 9784-9788, 1992 | 1351 | 1992 |
| Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis FM Brennan, A Jackson, D Chantry, R Maini, M Feldmann The Lancet 334 (8657), 244-247, 1989 | 1331 | 1989 |
| Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis T Hirano, T Matsuda, M Turner, N Miyasaka, G Buchan, B Tang, K Sato, ... European journal of immunology 18 (11), 1797-1802, 1988 | 1029 | 1988 |
| Development of anti-TNF therapy for rheumatoid arthritis M Feldmann Nature Reviews Immunology 2 (5), 364-371, 2002 | 920 | 2002 |
| Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis MJ Elliott, RN Maini, M Feldmann, A Long-Fox, P Charles, JA Bijl, ... The Lancet 344 (8930), 1125-1127, 1994 | 910 | 1994 |
| Role of interleukin‐1β in postoperative cognitive dysfunction M Cibelli, AR Fidalgo, N Terrando, D Ma, C Monaco, M Feldmann, ... Annals of neurology 68 (3), 360-368, 2010 | 866 | 2010 |
| The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis AM Malfait, R Gallily, PF Sumariwalla, AS Malik, E Andreakos, ... Proceedings of the National Academy of Sciences 97 (17), 9561-9566, 2000 | 817 | 2000 |
| Localization of tumor necrosis factor α in synovial tissues and at the cartilage–pannus junction in patients with rheumatoid arthritis CQ Chu, M Field, M Feldmann, RN Maini Arthritis & Rheumatism: Official Journal of the American College of …, 1991 | 794 | 1991 |
| Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis P Charles, MJ Elliott, D Davis, A Potter, JR Kalden, C Antoni, ... The Journal of Immunology 163 (3), 1521-1528, 1999 | 776 | 1999 |
| TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases M Feldmann, RN Maini Nature medicine 9 (10), 1245-1250, 2003 | 748 | 2003 |
